US2371862A - Therapeutic tablet - Google Patents

Therapeutic tablet Download PDF

Info

Publication number
US2371862A
US2371862A US437409A US43740942A US2371862A US 2371862 A US2371862 A US 2371862A US 437409 A US437409 A US 437409A US 43740942 A US43740942 A US 43740942A US 2371862 A US2371862 A US 2371862A
Authority
US
United States
Prior art keywords
acetate
aluminum sulphate
granulated
dry
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US437409A
Inventor
Irving B Wershaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dome Chemicals Inc
Original Assignee
Dome Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dome Chemicals Inc filed Critical Dome Chemicals Inc
Priority to US437409A priority Critical patent/US2371862A/en
Application granted granted Critical
Publication of US2371862A publication Critical patent/US2371862A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • My present invention relates to a new preparation ,inltablet form adapted to be used for making a solution for wetifdressings, compresses, wet packs, and immersiongoaths.
  • Another object of my present invention consists of producing tablets of the above type which are stable and thus storable for a practically unlimited time as long as they are kept dry and which nevertheless dissolve easily and quickly in water.
  • Still another object of my present invention consists of selecting the ingredients of these tablets in such a manner that the same can be easily compressed and hold firmly together after compressing.
  • my new preparation consists of a compressed mixture of dry acetate powder, aluminum sulphate and one or more binding agents bonding-the particles of said acetate powder and said aluminum sulphate together; the acetate used has to be adapted to form aluminum subacetate when mixed with aluminum sulphate and water. It is furthermore indispensable from the point of viewof the present invention that the aluminum sulphate used for these tablets be in a state substantially preventing reaction between this aluminum sulphate and the dry acetate powdercontained in the tablets.
  • I may coat the aluminum sulphate particles and thereby avoid reaction between them and the acetate present in the tablets.
  • a coating may retard the time of reaction during dissolution of the tablet in water, and is therefore not the best and simplest way of attaining the above described efiect.
  • this compressed mixture finally consists of nothing more than the powdered particles of these substances held together by a bind-
  • the contacting surfaces of these powdered particles are therefore relatively large in comparison with the amount of the substances contained in the compressed mixture; this results in a very great afiinity of these substances.
  • crystalline as used above and in the following description and claims defines not a granulated substance consisting of single particles composed each of powder particles of this substance and a binder, but a mass composed of uncrushed not powdered particles, namely, crystals of this substance.
  • the size of such crystals is in most cases-also if not separately indicatedlarger than the size of particles of a powder madeof this substance.
  • the acetate used for the new preparation is in granulated state, i. e., an acetate powder is used which is thoroughly mixed with a binding material and water; thereby the mixture of acetate and binder is granulated; thereafter, the granulated acetate is thoroughly dried.
  • the preferably crystalline aluminum sulphate granules are thoroughly mixed with another binder in dry state, preferably a water soluble starch or the like; the admixture of such a binder is advantageous as it bonds the particles in dry state very well to each other and easily dissolves when the tablet containing it is placed in water.
  • Such a binder accelerates decomposition of the tablet in water and does not retard the reaction between the aluminum sulphate and acetate containedinit.
  • the finished tablet consists of two mixtures, namely of a granulated acetate consisting of acetate powder thoroughly mixed with a binding agent, as gelatin, acacia, or the like, and of an intimate mixture of aluminum sulphate and a binder which is easily soluble in water, for instance a water soluble starch or the like. These two mixtures, in turn, are thoroughly mixed before being compressed into tablets.
  • a binding agent as gelatin, acacia, or the like
  • aluminum sulphate and a binder which is easily soluble in water, for instance a water soluble starch or the like.
  • boric acid powder is added as so-called lubricant. It is evident that also other substances adapted to serve as lubricants may be used instead of this boric acid.
  • a preparation which proved to be very satisfactory therapeutically contains 30% to 40% of powdered calcium acetate, 0.6% to 1.2% of powdered acacia, 40% to 60% of aluminum sulphate in crystalline granular state, 8% to of a water soluble starch. and a small percentage, preferably not more than 3%, of powdered boric acid; all these ingredients are in completely dry state and after thorough mixing are compressed into tablets which are solid and stable, i. e., may be stored without any danger of decomposition for a practically unlimited time.
  • Tablets of the type claimed by me can, for instance, be produced in the following way:
  • acacia are in powder form and are put through a number 20 sieve before granulation.
  • This finished mass is then compressed into tablets in well-known way, for instance by means of a so-called Stokes tablet machine.
  • the tablet produced in this manner is solid and stable when stored in a dry cool place and its ingredients will not react with each other without being dissolved in water.
  • a therapeutically active solid and stable preparation in tablet form consisting of a compressed mixture containing a dry water-soluble metallic acetate powder adapted to form aluminum subacetate when mixed with aluminum sulphate and water, dry crystalline aluminum sulphate in not-powdered form the single crystals of which have a substantially larger size than that of the single particles of said metallic acetate powder, and at least one binding agent bonding the particles of said metallic acetate powder and the crystals of said aluminum sulphate together.
  • a therapeutically active solid and stable preparation in tablet form comprising a compressed mixture containing dry powdered calcium acetate, dry crystalline not-powdered aluminum sulphate, the single crystals of which have a substantially larger size than that of the single particles of said acetate powder, and at least one binding agent bonding the particles of said powdered calcium acetate and said dry crystalline aluminum sulphate together.
  • a therapeutically active solid and stable preparation in tablet form comprising a compressed mixture containing a dry water-soluble granulated metallic acetate powder adapted toreact with aluminum sulphate and to form aluminum subacetate when mixed with aluminum sulphate and water, dry crystalline aluminum sulphate in not-powdered state the single crystals of which have a substantially larger size than that or the single metallic acetate particles 01' said granulated metallic acetate powder and at least one binding agent bonding said dry crystalline aluminum sulphate and said granulated metallic acetate powder-together.
  • a therapeutically active solid and stable preparation in tablet i'orm comprising a compressed mixture containing dry granulated calcium acetate powder, crystalline aluminum sulphate in not-powdered state the'gingle crystals of which have a substantially larger size than that of the single calcium acetate particles of said granulated calcium acetate powder, and a binding agent bonding said crystalline aluminum sulphate and said granulated calcium acetate powder toether.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented Mar. 20, 1945 as'zrsez 'rnnaarsnric TABLET Irving Wershaw, New York, N. Y., assignor to Dome? Chemicals Incorporated, New York,
hrs-baths. nppueaflon April 2, 1942, w
" Serial No. 437,409
4 Claims. (Cl. 167-58) My present invention"'relates to a new preparation ,inltablet form adapted to be used for making a solution for wetifdressings, compresses, wet packs, and immersiongoaths.
It is the main object of the present invention to provide for a new, therapeutically active, solid, and stable preparation in tablet form which contains all ingredients needed for producing a solution for wet dressings.
Another object of my present invention consists of producing tablets of the above type which are stable and thus storable for a practically unlimited time as long as they are kept dry and which nevertheless dissolve easily and quickly in water.
Still another object of my present invention consists of selecting the ingredients of these tablets in such a manner that the same can be easily compressed and hold firmly together after compressing.
With the above objects in view, my new preparation consists of a compressed mixture of dry acetate powder, aluminum sulphate and one or more binding agents bonding-the particles of said acetate powder and said aluminum sulphate together; the acetate used has to be adapted to form aluminum subacetate when mixed with aluminum sulphate and water. It is furthermore indispensable from the point of viewof the present invention that the aluminum sulphate used for these tablets be in a state substantially preventing reaction between this aluminum sulphate and the dry acetate powdercontained in the tablets.
I have found that for the new preparation manydifferent acetates maybe used, such as the acetates of magnesium, cadmium, barium, strontium, and other similar metals; I prefer, however, to use calcium acetate as with this acetate I have obtained the best results.
The above mentioned eifect, namely that the aluminum sulphate should be in a state substantially preventing reaction of this sulphate with the acetate present in the tablets, can be obtained in the most different ways.
Thus, for instance, I may coat the aluminum sulphate particles and thereby avoid reaction between them and the acetate present in the tablets. However, such a coating may retard the time of reaction during dissolution of the tablet in water, and is therefore not the best and simplest way of attaining the above described efiect.
Another proposal to obtain the desired effect is based on the observation that the aflinity of the aluminum sulphate and the acetate is the greatest when they are used in powdered form, irrespectively of the fact whether this powder is added to the tablets in granulated or in ungranulated state. It should be stressed that the term granulated as used above and in the following description and claims indicates that the granulated substance has originally been in powder form, has then been mixed with a binding material and water, and thereafter dried. Thus, each particle of such a granulated substance consists of a number of particles of this substance itself and binding material holding these particles together. If two substances, each of which is in granulated form, are mixed and compressed, this compressed mixture finally consists of nothing more than the powdered particles of these substances held together by a bind- The contacting surfaces of these powdered particles are therefore relatively large in comparison with the amount of the substances contained in the compressed mixture; this results in a very great afiinity of these substances.
It have found that by using crystalline aluminum sulphate the single crystals of which have a substantially larger size than that of the single acetate powder particles, I obtained very good results, i. e., the afiim'ty of crystalline aluminum sulphate of the above type and granulated acetate powder proved to be substantially less than the affinity between these same substances when they ar both in powdered or granulated state. This makes possible combination of all needed ingredients in one single tablet without any danger of reaction as long as this tablet is kept dry. It should be stressed that the term crystalline as used above and in the following description and claims defines not a granulated substance consisting of single particles composed each of powder particles of this substance and a binder, but a mass composed of uncrushed not powdered particles, namely, crystals of this substance. The size of such crystals is in most cases-also if not separately indicatedlarger than the size of particles of a powder madeof this substance.
The acetate used for the new preparation is in granulated state, i. e., an acetate powder is used which is thoroughly mixed with a binding material and water; thereby the mixture of acetate and binder is granulated; thereafter, the granulated acetate is thoroughly dried. The preferably crystalline aluminum sulphate granules are thoroughly mixed with another binder in dry state, preferably a water soluble starch or the like; the admixture of such a binder is advantageous as it bonds the particles in dry state very well to each other and easily dissolves when the tablet containing it is placed in water. Thus,
such a binder accelerates decomposition of the tablet in water and does not retard the reaction between the aluminum sulphate and acetate containedinit.
Thus, the finished tablet consists of two mixtures, namely of a granulated acetate consisting of acetate powder thoroughly mixed with a binding agent, as gelatin, acacia, or the like, and of an intimate mixture of aluminum sulphate and a binder which is easily soluble in water, for instance a water soluble starch or the like. These two mixtures, in turn, are thoroughly mixed before being compressed into tablets.
In order to avoid sticking of the mixed ingredients to the punches of the tablet making machine during compressing, boric acid powder is added as so-called lubricant. It is evident that also other substances adapted to serve as lubricants may be used instead of this boric acid.
A preparation which proved to be very satisfactory therapeutically contains 30% to 40% of powdered calcium acetate, 0.6% to 1.2% of powdered acacia, 40% to 60% of aluminum sulphate in crystalline granular state, 8% to of a water soluble starch. and a small percentage, preferably not more than 3%, of powdered boric acid; all these ingredients are in completely dry state and after thorough mixing are compressed into tablets which are solid and stable, i. e., may be stored without any danger of decomposition for a practically unlimited time.
Tablets of the type claimed by me can, for instance, be produced in the following way:
First, about 50.6 parts of dry granular aluminum sulphate ,in crystalline state are intimately mixed with about 12.4 parts of dry soluble starch and about 1.5 parts of powdered boric acid. The granules of the aluminum sulphate are of such a size that they may be put through a No. 16 sieve; the starch and boric acid are in powder form and are put through a No. 20 sieve before being added to the crystalline aluminum sulphate; the sulphate, starch, and boric acid are then thoroughly mixed.
Then, separately from the above mixture, about 34.5 parts of calcium acetate are finely granulated with about one part of acacia and thereafter dried. Both the calcium acetate and the Each of these tablets contains about 50.6% of granular aluminum sulphate in crystalline state intimately mixed with about 12.4% of a soluble starch and about l.5% of powdered boric acid,
and about 34.5% of powdered calcium acetate This basic aluminum acetate solution is then used as a wet dressing in all cases where such a dressing is advisable.
It will be understood that each of the elements described above, or two or more of them together, may also find a useful application in other preparations differing from those described above.
While I have illustrated and described the invention as embodied in preparations for making wet dressings, I do not intend to be limited to the details shown, since various modifications and structural changes may be made without departing in any way from the spirit of my invention.
Without further analysis, the foregoing will so fully reveal the gist of my invention that others can by applying current knowledge readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic 49 or specific aspects of this invention and, therefore,
acacia are in powder form and are put through a number 20 sieve before granulation.
thorough and even drying.
Thereafter these two mixtures, namely, the sulphate, starch and boric acid mixture on the one hand and the granulated calcium acetateacacia mixture on the other hand, are thoroughly mixed. The thus prepared final mixture represents the finished mass for the new preparation.
This granulation is carried out in a Well-known way,'
This finished mass is then compressed into tablets in well-known way, for instance by means of a so-called Stokes tablet machine. The tablet produced in this manneris solid and stable when stored in a dry cool place and its ingredients will not react with each other without being dissolved in water.
such adaptations should and are intended to be comprehended within the meaning and range of equivalence of the following claims.
What I claim as 'new'and desire to secure by Letters Patent is:
i. A therapeutically active solid and stable preparation in tablet form, consisting of a compressed mixture containing a dry water-soluble metallic acetate powder adapted to form aluminum subacetate when mixed with aluminum sulphate and water, dry crystalline aluminum sulphate in not-powdered form the single crystals of which have a substantially larger size than that of the single particles of said metallic acetate powder, and at least one binding agent bonding the particles of said metallic acetate powder and the crystals of said aluminum sulphate together.
2. A therapeutically active solid and stable preparation in tablet form, comprising a compressed mixture containing dry powdered calcium acetate, dry crystalline not-powdered aluminum sulphate, the single crystals of which have a substantially larger size than that of the single particles of said acetate powder, and at least one binding agent bonding the particles of said powdered calcium acetate and said dry crystalline aluminum sulphate together.
3. A therapeutically active solid and stable preparation in tablet form, comprising a compressed mixture containing a dry water-soluble granulated metallic acetate powder adapted toreact with aluminum sulphate and to form aluminum subacetate when mixed with aluminum sulphate and water, dry crystalline aluminum sulphate in not-powdered state the single crystals of which have a substantially larger size than that or the single metallic acetate particles 01' said granulated metallic acetate powder and at least one binding agent bonding said dry crystalline aluminum sulphate and said granulated metallic acetate powder-together.
4. A therapeutically active solid and stable preparation in tablet i'orm, comprising a compressed mixture containing dry granulated calcium acetate powder, crystalline aluminum sulphate in not-powdered state the'gingle crystals of which have a substantially larger size than that of the single calcium acetate particles of said granulated calcium acetate powder, and a binding agent bonding said crystalline aluminum sulphate and said granulated calcium acetate powder toether.
IRVING B. WERSHAW.
US437409A 1942-04-02 1942-04-02 Therapeutic tablet Expired - Lifetime US2371862A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US437409A US2371862A (en) 1942-04-02 1942-04-02 Therapeutic tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US437409A US2371862A (en) 1942-04-02 1942-04-02 Therapeutic tablet

Publications (1)

Publication Number Publication Date
US2371862A true US2371862A (en) 1945-03-20

Family

ID=23736308

Family Applications (1)

Application Number Title Priority Date Filing Date
US437409A Expired - Lifetime US2371862A (en) 1942-04-02 1942-04-02 Therapeutic tablet

Country Status (1)

Country Link
US (1) US2371862A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827420A (en) * 1956-10-24 1958-03-18 Irving B Wershaw Therapeutic tablets
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
US5370867A (en) * 1991-10-17 1994-12-06 Kao Corporation Bath composition
EP2161022A1 (en) 2008-09-05 2010-03-10 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Production of phosphate connectors and phosphate connectors produced according to the method

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827420A (en) * 1956-10-24 1958-03-18 Irving B Wershaw Therapeutic tablets
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
US5370867A (en) * 1991-10-17 1994-12-06 Kao Corporation Bath composition
EP2161022A1 (en) 2008-09-05 2010-03-10 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Production of phosphate connectors and phosphate connectors produced according to the method

Similar Documents

Publication Publication Date Title
US3133863A (en) Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US2540253A (en) Granulation process
GB1097955A (en) An organopolysiloxane-containing tablet
GB953960A (en) Improvements in or relating to the production of compressed therapeutic tablets
ES312728A1 (en) Procedure for the preparation of compresses by compression of dust mixtures. (Machine-translation by Google Translate, not legally binding)
US3308217A (en) Method of granulating materials for subsequent forming into tablets
GB1028792A (en) A process of manufacturing water-dispersible tablets and the like
US3836618A (en) Process for the uniform distribution of a drug on a granulated base
US2980589A (en) Process for producing anhydrous granulation of a medicinally active waterlabile powder
US3121663A (en) Carbon dioxide releasing laxative suppository
US20020117088A1 (en) Agglomeration of hydraulic cement powder
US2371862A (en) Therapeutic tablet
US2951791A (en) Use of calcium silicate in tablet compressing
HK59894A (en) Pharmaceutical compositions containing clodronate, and process for their preparation
GB835532A (en) Production of timed release medicaments
GB1287431A (en) Improvements in pharmaceutical formulations
GB1340351A (en) Method for the preparation of fusible charge batches
US4495213A (en) Water-soluble sweetening tablet
JPS5832820A (en) Tablet
US2801951A (en) Stabilized analgesic compositions
KR910011241A (en) Spray drying to prepare pharmaceutical powder compositions that can be compressed directly into tablets
US4245054A (en) Process for the manufacture of a dry mixture for insulating stucco or plaster
US1950956A (en) Method of coating chloramine and product thereof
US3493659A (en) Compositions and process for the production thereof
IE33480L (en) Sustained release tablets